Biologics Inc. (RTI) (Nasdaq: RTIX), a leading processor of
orthopedic and other biologic implants, in response to inquiries
regarding Medtronic's announced acquisition of Osteotech stated today
that the relationship between Medtronic and RTI Biologics continues to
be strong, with no changes near-term.
?We have received confirmation from Medtronic that our relationship is
business as usual and they remain supportive of our current agreement,
which runs through June 2014,? said Brian K. Hutchison, RTI chairman and
CEO. ?Both companies have taken several steps over the years to
continuously improve our relationship, and we have been assured that
Medtronic will continue down that path with RTI. At this time we expect
to continue to meet Medtronic's spinal allograft needs with
About RTI Biologics Inc.
Biologics Inc. is a leading provider of sterile biological
implants for surgeries around the world with a commitment to
advancing science, safety and innovation. RTI prepares human donated
tissue and bovine tissue for transplantation through extensive testing
and screening, precision shaping and using proprietary, validated
processes. These allograft and xenograft implants are used in
orthopedic, dental, hernia and other specialty surgeries.
RTI's innovations continuously raise the bar of science and safety for
biologics from being the first company to offer precision-tooled bone
implants and assembled technology to maximize each gift of donation, to
inventing validated sterilization processes that include viral
inactivation steps. Two such processes the BioCleanse
Tissue Sterilization Process and the Tutoplast®
Tissue Sterilization Process have a combined record of more than
two million implants distributed with zero incidence of
allograft-associated infection. These processes have been validated by
tissue type to inactivate or remove viruses, bacteria, fungi and spores
from the tissue while maintaining biocompatibility and functionality.
RTI's worldwide corporate headquarters are located in Alachua, Fla.,
with international locations in Germany and France. The company is
accredited by the American Association of Tissue Banks in the United
Forward Looking Statement
This communication contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based on management's current
expectations, estimates and projections about our industry, our
management's beliefs and certain assumptions made by our management.
Words such as "anticipates," "expects," "intends," "plans," "believes,"
"seeks," "estimates," variations of such words and similar expressions
are intended to identify such forward-looking statements. In addition,
except for historical information, any statements made in this
communication about anticipated financial results, growth rates, new
product introductions, future operational improvements and results or
regulatory approvals or changes to agreements with distributors also are
forward-looking statements. These statements are not guarantees of
future performance and are subject to risks and uncertainties, including
the risks described in public filings with the U.S. Securities and
Exchange Commission (SEC). Our actual results may differ materially from
the anticipated results reflected in these forward-looking statements.
Copies of the company's SEC filings may be obtained by contacting the
company or the SEC or by visiting RTI's Web site at www.rtix.com
or the SEC's Web site at www.sec.gov.
RTI Biologics Inc., Alachua
Robert Jordheim, Chief Financial Officer
Crites Wacker, APR, Corporate Communications, 386-418-8888